Rna Diagnostics’s innovative RDA™ Cancer Chemotherapy Guidance Assay and Medtronic’s leading edge Symplicty™ Renal Denervation System are considered disruptive technologies and were selected as lead projects for MaRS EXCITE. GCA HealthCare Consulting has provided specialized consultancy services to both firms to support the market development of these breakthrough technologies.

MaRS Excellence in Clinical Innovation and Technology Evaluation (“EXCITE”) goal is to enable better health technologies to get to market faster – leading to improved health outcomes. EXCITE will help companies increase the likelihood of success for their breakthrough technology-based health innovations through a more effective approach to navigating the required approvals, adoption and uptake.

EXCITE unifies Ontario’s best-in-class approach to medical technology testing, bringing together a broad spectrum of research under one harmonized platform based on relationships brokered with academic health research facilities across the province.

GCA HealthCare Principal, Gino Ariano stated “ both Medtronic and Rna Diagnostics are focused on delivering innovative medical technologies that provide meaningful improvements in patient outcomes”, GCA HealthCare Consulting is proud to support the ongoing growth and development of both organizations”.